CAR T Cells Are Reshaping the Future of Cancer Treatment!

The revolutionary CAR T Cell Therapy is changing the scenario of how we deal with cancer, making it more personal and powerful. This latest therapy uses a patient's own immune cells and genetically modifies them to target and des..

The Role Of Immunotherapy In Lymphoma Treatment

If you're reading this, you or maybe one of your loved ones is on a journey that no one ever plans to take—the path of facing cancer. We understand that this road is filled with uncertainties, fears, and moments when it feel..

Project Renewal, Temodar, temozolomide, Xeloda

New and updated indications are approved by FDA for temozolomide under Project Renewal

Nov 2023: Under Project Renewal, an Oncology Centre of Excellence (OCE) initiative aimed at updating labelling information for older oncology drugs to ensure information is clinically meaningful and scientifically up-to-date, th..

CAR T-Cell, CAR therapy, Immunotherapy, T cell therapy

Is CAR T-Cell Therapy Available In India?

Have you ever wondered if there is a powerful way to fight cancer? Now just imagine if one day you found a ray of hope in your fight against cancer, a treatment that uses the power of your body's own immune system to target an..

Bevacizumab, Lonsurf, Taiho Oncology, tipiracil, Trifluridine

Trifluridine and tipiracil with bevacizumab is approved by FDA for previously treated metastatic colorectal cancer

August 2023: For metastatic colorectal cancer (mCRC) that has already been treated with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy..

Dostarlimab-gxly, GlaxoSmithKline, Jemperli

Dostarlimab-gxly with chemotherapy is approved by the FDA for endometrial cancer

August 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline), followed by dostarlimab-gxly as a single agent, was approved by the Food and Drug Administration for the treatment of primary advanced or recurrent endometrial cancer (EC..

anthracycline, cytarabine, Daiichi Sankyo, quizartinib, Vanflyta

Quizartinib is approved by the FDA for newly diagnosed acute myeloid leukemia

August 2023: The treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test, with standard cytarabine and anthracycl..

ALL, Amgen, Blinatumomab, Blincyto, minimal residual disease, MRD

A trial shows that blinatumomab could be used in more ways to treat ALL

Results from a big clinical trial show that adding blinatumomab (Blincyto) to the treatment of people with acute lymphoblastic leukaemia (ALL) who are in remission, even if there are no signs of their disease, can help them live l..

bispecific T-cell engager, BiTE, BiTE therapy, multiple myeloma

Development and future potential of the BiTE (bispecific T-cell engager) platform

Immuno-oncology is a way to treat cancer by using the body's immune system. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that binds a patient's own T cells to cancer cells. Because BiTE techno..

Cartesian Therapeutics, Descartes-08, Lancet, myasthenia gravis

Rare autoimmune disorder myasthenia gravis treated by CAR-T therapy

July 2023: Evidence from a small-scale clinical trial shows that myasthenia gravis, an autoimmune disorder of the nervous system, could be treated with a variation of CAR-T, an advanced blood cancer immunotherapy. The modifie..